Butterfly Biosciences
Butterfly Biosciences is a pre-market medical device company developing an AI-powered Visual SIS diagnostic and operative platform plus a visual embryo transfer system for gynecologic, fertility, and IVF use by Ob/Gyns, primary care physicians, and fertility clinics.
- Company typePrivate
- Founded2021
- HeadquartersMarina Del Rey, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Butterfly Biosciences does
Butterfly Biosciences is a private, pre-market medical device company developing an integrated platform for gynecologic and fertility care. Its flagship product, Butterfly InSights, is a next-generation AI-powered Visual Saline Infusion Sonography system that enables non-invasive intrauterine examination, biopsy, and operative procedures such as polyp, cyst, and fibroid removal in a single office visit, replacing ultrasound-based evaluation and reducing diagnostic timelines from months to a single encounter. A second core device, Butterfly VET, is positioned as the world's first visual embryo transfer system, providing direct visualization of catheter placement during IVF to standardize transfer precision regardless of operator skill.
The platform is anchored by BBioConnect, a HIPAA-compliant connected application that applies machine learning to large case repositories for pathology identification and clinical decision support, with multimodal data inputs including intrauterine video and structured patient data. The system includes integrated safety features (fluid deficit monitoring, intrauterine pressure management, HD visualization) and is designed for use by Ob/Gyn specialists, primary care physicians, and fertility clinic staff without requiring specialist training.
The company has not yet generated revenue. It targets over 40,000 Ob/Gyns in the United States and 60,000-plus globally, with a planned FDA 510K clearance and US market entry in 2027 following pre-commercialization activities in 2025-2026. Revenue mechanics are planned across hardware sales, recurring consumables, and potential BBioConnect software licensing, with procedures designed to be reimbursable under standard insurance and accessible to cash-pay patients. The company is headquartered in Marina del Rey, California, with an operational office in Punta de Mita, Mexico, and partnerships with USC Viterbi Innovation, Homu Health Ventures, and Punta Mita Hospital.
Butterfly Biosciences firmographics
Firmographics- Name
- Butterfly Biosciences
- Legal name
- Butterfly Biosciences Inc.
- Website
- https://butterfly.bio
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Butterfly Biosciences is a pre-market medical device company developing an AI-powered Visual SIS diagnostic and operative platform plus a visual embryo transfer system for gynecologic, fertility, and IVF use by Ob/Gyns, primary care physicians, and fertility clinics.
- Ownership category
- akta.pro rank
Butterfly Biosciences industry classification
Industry- Product category
- Women's Health Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA)
- akta.pro secondary industries
- Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG), Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine) (HLAHAEAL)
Keywords
Where Butterfly Biosciences is headquartered
LocationHeadquarters
- HQ city
- Marina Del Rey
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Butterfly Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales and Consumables: The company is developing a platform of medical devices (Butterfly InSights, Butterfly VET) and associated consumables/accessories for gynecologic and fertility procedures. Revenue will be generated through device sales and recurring consumable revenue to physician offices and fertility clinics. The company is pre-market with commercialization planned for 2025-2026.
- AI Diagnostic Services: BBioConnect AI/ML platform providing diagnostic decision support to clinicians. Revenue may be generated through software licensing or subscription to the connected diagnostic platform.
- Insurance Reimbursement: Procedures performed using the Butterfly platform are designed to be reimbursable with most insurance plans, creating a revenue pathway aligned with standard healthcare billing practices.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Butterfly Biosciences product offering
Product offeringCore offering
Butterfly Biosciences develops and plans to sell an integrated platform of medical devices for in-office gynecologic and fertility care, including Butterfly InSights (AI-powered Visual Saline Infusion Sonography for diagnostic and operative uterine care), Butterfly VET (the world's first visual embryo transfer system for IVF), and BBioConnect (a HIPAA-compliant AI/ML connected application providing pathology identification and decision support). The platform replaces surgery with reimbursable in-office procedures, enabling any physician—not just gynecologists—to perform high-precision intrauterine diagnosis and treatment in a single visit.
Product overview
Butterfly Biosciences offers a unified platform approach to gynecologic and fertility care consisting of three core products: Butterfly InSights (Visual Saline Infusion Sonography) for AI-powered diagnostic and operative uterine examination; Butterfly VET (Visual Embryo Transfer), the world's first visual embryo transfer system; and BBioConnect, an AI-powered connected app that integrates with InSights for pathology identification and clinical decision support. The platform enables in-office diagnosis and treatment that replaces surgery, designed for use by OB/GYNs, primary care physicians, and fertility specialists.
Differentiator
Problem solved
Functional benefit
Brands
- Butterfly InSights: Next-Gen AI Powered Diagnostic and Operative Uterine Care platform (Visual Saline Infusion Sonography)
- Butterfly VET
- BBioConnect
Products and services
- Butterfly InSights Next-generation AI-powered Visual Saline Infusion Sonography (SIS) system for in-office diagnostic and operative uterine care that provides non-invasive intrauterine examination and biopsy with direct HD visualization, replacing ultrasound-based standard of care. Supports targeted biopsy, polyp/cyst/septoplasty removal, IUD removal, retained products of conception removal, and endometrial ablation. Designed for use by Ob/Gyns, primary care physicians, and fertility specialists in physician offices.
- Butterfly VET (Visual Embryo Transfer) World's first visual embryo transfer system that enables direct visualization of intrauterine space during IVF embryo transfer, providing precise catheter tip location, steerability, and built-in automation that reproduces the techniques of top fertility specialists. For fertility clinics and reproductive endocrinologists performing IVF, optimizing patient comfort (pain score <1 on Wong-Baker scale) and standardizing embryo transfer regardless of anatomical variation.
- BBioConnect HIPAA-compliant AI-powered connected application integrated with Butterfly InSights that provides pathology identification, patient records management, data storage, and AI/ML-driven clinical decision support. Harnesses extensive case data repositories to refine diagnostic precision in reproductive health and reduce the complexity of gynecologic pathology identification for non-specialist physicians.
Quantifiable outcome
- Diagnostic timeline reduced from 4-6 months to single patient office visit
- +3 more outcomes
Companies that use Butterfly Biosciences
Customer profileSegments4 records
Ideal customer profiles3 records
Butterfly Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
Butterfly Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Punta Mita HospitalminorMedical facility partnership providing potential clinical collaboration, research, or healthcare delivery partnership in the Mexican market.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Butterfly Biosciences competitors and assessment
Company assessmentEmerging players
- TMRW Life Sciences: Automation and management technology for IVF labs (cryo storage/specimen management). Comparable as a technology-driven entrant modernizing fertility clinic workflows.
- Alife Health: AI-powered software to improve IVF outcomes and clinical decision-making. Overlaps with Butterfly's AI diagnostic ambitions in fertility.
- AiVF: AI platform for embryo evaluation and IVF decision support. Comparable to Butterfly's BBioConnect AI-driven reproductive diagnostics, though focused on embryology imaging rather than devices.
- Conceivable Life Sciences: Building automated/robotic IVF procedures to standardize fertility treatment. Comparable to Butterfly VET's automation of embryo transfer technique.
Broad incumbents
- Hologic: Leading women's health diagnostics and surgical company with gynecologic imaging and intrauterine procedure devices. Overlaps with Butterfly's gynecologic diagnosis/treatment focus at a much larger scale.
- CooperSurgical: Major supplier of fertility/IVF consumables, embryo transfer catheters, and women's health devices. Overlaps directly with Butterfly's fertility and gynecologic device markets but as a broad incumbent portfolio.
- Vitrolife: Global IVF products and technology company serving fertility clinics with media, devices and workflow tools. Comparable in targeting IVF/embryo transfer clinical workflows.
- Olympus (Gynecology): Major provider of hysteroscopy and endoscopic visualization systems used for intrauterine examination and operative procedures. Overlaps with Butterfly InSights' visualization-guided uterine care.
- Minerva Surgical: Provides minimally invasive gynecologic devices including endometrial ablation and hysteroscopic tissue removal used in-office. Comparable to Butterfly InSights' operative uterine care use cases.
Direct peers
- Femasys: Develops in-office medical devices for women's reproductive health and fertility (e.g., permanent birth control, intrauterine insemination, biopsy). Directly comparable in its office-based gynecologic/fertility device model targeting Ob/Gyns.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Butterfly Biosciences social profiles
Digital presenceButterfly Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Butterfly Biosciences leadership team
Management profileNumber of profiles
Profiles13 records
Butterfly Biosciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Butterfly Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Butterfly Biosciences
What does Butterfly Biosciences do?
Butterfly Biosciences develops and plans to sell an integrated platform of medical devices for in-office gynecologic and fertility care, including Butterfly InSights (AI-powered Visual Saline Infusion Sonography for diagnostic and operative uterine care), Butterfly VET (the world's first visual embryo transfer system for IVF), and BBioConnect (a HIPAA-compliant AI/ML connected application providing pathology identification and decision support). The platform replaces surgery with reimbursable in-office procedures, enabling any physician—not just gynecologists—to perform high-precision intrauterine diagnosis and treatment in a single visit.
Is Butterfly Biosciences a public or private company?
Butterfly Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Butterfly Biosciences founded?
Butterfly Biosciences was founded in 2021. It employs 1 to 10 people.
Where is Butterfly Biosciences based?
Butterfly Biosciences is headquartered in Marina Del Rey, United States, in the North America region.
How does Butterfly Biosciences make money?
Three revenue lines are on record. Medical Device Sales and Consumables are the primary driver. The others are AI Diagnostic Services and insurance Reimbursement.
Who are Butterfly Biosciences's main competitors?
Emerging players on record are TMRW Life Sciences, Alife Health, AiVF and Conceivable Life Sciences. Broad incumbents are Hologic, CooperSurgical, Vitrolife, Olympus (Gynecology) and Minerva Surgical. Femasys is listed as a direct peer.
Does Butterfly Biosciences have an API?
No public API is recorded for Butterfly Biosciences.
What industry is Butterfly Biosciences in?
Butterfly Biosciences's product category is Women's Health Medical Devices. Its primary akta.pro industry code is HLALAHAA, Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation), with a secondary code of HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems. Its NAICS code is 3391 and its SIC code is 3841.